Kymera Therapeutics (KYMR) EBIAT (2019 - 2025)
Historic EBIAT for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$82.2 million.
- Kymera Therapeutics' EBIAT fell 3150.74% to -$82.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.1 million, marking a year-over-year decrease of 7621.96%. This contributed to the annual value of -$223.9 million for FY2024, which is 5232.37% down from last year.
- Per Kymera Therapeutics' latest filing, its EBIAT stood at -$82.2 million for Q3 2025, which was down 3150.74% from -$76.6 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' EBIAT ranged from a high of -$13.1 million in Q1 2021 and a low of -$82.2 million during Q3 2025
- Its 5-year average for EBIAT is -$44.7 million, with a median of -$40.9 million in 2023.
- Per our database at Business Quant, Kymera Therapeutics' EBIAT soared by 5878.96% in 2023 and then crashed by 39242.76% in 2024.
- Quarter analysis of 5 years shows Kymera Therapeutics' EBIAT stood at -$33.9 million in 2021, then dropped by 2.85% to -$34.9 million in 2022, then skyrocketed by 58.79% to -$14.4 million in 2023, then crashed by 392.43% to -$70.8 million in 2024, then dropped by 16.15% to -$82.2 million in 2025.
- Its last three reported values are -$82.2 million in Q3 2025, -$76.6 million for Q2 2025, and -$65.6 million during Q1 2025.